Search Within

Ellin Berman

Formats
  1. Journal Article (94)
  2. Meeting Abstract (66)
  3. Conference Paper (6)
  4. Guidelines (2)
  5. Review (2)
  6. Book Section (1)
  7. Correspondence (1)
  8. Editorial (1)
Groups
  1. Adult Leukemia (173)
  2. Center for Hematologic Malignancies (173)
  3. Department of Medicine (173)
  4. Hematologic Malignancies, Division of (173)
  5. Sloan Kettering Institute Faculty (44)
  6. Molecular Pharmacology and Chemistry Program Faculty (41)

More Groups

People
  1. Bayard Clarkson (29)
  2. Timothy Gee (26)
  3. Martin Tallman (17)
  4. Peter Maslak (17)
  5. Sanford Kempin (17)
  6. David Scheinberg (15)

More People

Years
  1. 2024 (4)
  2. 2023 (5)
  3. 2022 (4)
  4. 2021 (3)
  5. 2020 (7)
  6. 2019 (9)

More Years

Publications
  1. Blood (52)
  2. Journal of Clinical Oncology (20)
  3. Journal of the National Comprehensive Cancer Network (12)
  4. Leukemia (11)
  5. Leukemia Research (6)
  6. Bone Marrow Transplantation (5)

More Publications

Publishers
  1. American Society of Hematology (53)
  2. American Society of Clinical Oncology (20)
  3. Nature Publishing Group (17)
  4. Harborside Press (12)
  5. Elsevier Inc. (9)
  6. American Association for Cancer Research (8)

More Publishers

Results (173)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Chronic myeloid leukemia, version 2.2021: NCCN Clinical Practice Guidelines in Oncology
    Guidelines

    Deininger, M. W.; Shah, N. P.; Altman, J. K.; Berman, E.; Bhatia, R.; Bhatnagar, B.; DeAngelo, D. J.; Gotlib, J.; Hobbs, G.; Maness, L.; more...
    Journal of the National Comprehensive Cancer Network (2020)

    Fulltext@MSK | Save
  • Retrospective independent review of arterial occlusive events (AOEs) in the ponatinib phase 2 PACE trial (NCT01207440) in patients with Philadelphia chromosome positive (Ph+) leukemia
    Meeting Abstract

    Januzzi, J.; Garasic, J.; Kasner, S.; McDonald, V.; Petrie, M.; Seltzer, J.; Mauro, M.; Croce, K.; Berman, E.; Deininger, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukaemia who have common AML comutations or a high FLT3-internal tandem duplication allelic ratio
    Meeting Abstract

    Levis, M. J.; Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Chou, W. C.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Overcoming adaptive therapy resistance in AML by targeting immune response pathways
    Meeting Abstract

    Melgar, K. M.; Jones, L. M.; Walker, M.; Bolanos, L. C.; Hueneman, K.; Wunderlich, M.; Jiang, J. K.; Wilson, K.; Zhang, X.; Sutter, P.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: Results from the phase 3 ADMIRAL trial
    Meeting Abstract

    Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Emerging mutations at relapse in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia who received gilteritinib therapy in the phase 3 ADMIRAL trial
    Meeting Abstract

    Smith, C. C.; Levis, M. J.; Perl, A. E.; Martinelli, G.; Neubauer, A.; Berman, E.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Chou, W. C.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: Results from the phase 3 admiral trial
    Meeting Abstract

    Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; more...
    Haematologica (2019)

    Fulltext@MSK | Save
  • Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML
    Journal Article

    Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; more...
    New England Journal of Medicine (2019)

    Fulltext@MSK | Save
  • Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio
    Meeting Abstract

    Levis, M. J.; Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Chou, W. C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the phase III ADMIRAL trial
    Meeting Abstract

    Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save